Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Abstract

Context: Pegvisomant is a specific GH receptor antagonist that is able to normalize serum IGF-I concentrations in most patients with acromegaly. The impact of pegvisomant on insulin sensitivity and substrate metabolism is less well described.

Patients and Methods: We assessed basal and insulin-stimulated (euglycemic clamp) substrate metabolism in seven patients with active acromegaly before and after 4-wk pegvisomant treatment (15 mg/d) in an open design.

Results: After pegvisomant, IGF-I decreased, whereas GH increased (IGF-I, 621 ± 82 vs. 247 ± 33 μg/liter, P = 0.02; GH, 5.3 ± 1.5 vs. 10.8 ± 3.3 μg/liter, P = 0.02). Basal serum insulin and plasma glucose levels decreased after treatment (insulin, 54 ± 5.9 vs. 42 ± 5.3 pmol/liter, P = 0.001; glucose, 5.7 ± 0.1 vs. 5.3 ± 0.0 mmol/liter, not significant), whereas palmitate kinetics were unaltered. During the clamp, the glucose infusion rate increased after pegvisomant (3.1 ± 0.5 vs. 4.4 ± 0.6 mg/kg·min, P = 0.02), whereas the suppression of endogenous glucose production tended to increase (0.7 ± 0.0 vs. 0.5 ± 0.1 mg/kg·min, not significant). Total resting energy expenditure decreased after pegvisomant treatment (1703 ± 109 vs. 1563 ± 101 kcal/24 h, P = 0.03), but the rate of lipid oxidation did not change significantly.

Conclusions: 1) Pegvisomant treatment for 4 wk improves peripheral and hepatic insulin sensitivity in acromegaly. 2) This is associated with a decrease in resting energy expenditure, whereas free fatty acid metabolism is unaltered. 3) The data support the important direct effects of GH on glucose metabolism and add additional benefits to pegvisomant treatment for acromegaly.

Copyright © 2007 by The Endocrine Society
Issue Section:
Endocrine Care
You do not currently have access to this article.
Download all slides